Aarti Drugs Reports 6% YoY Revenue Growth in Q1 FY26, PAT Surges 62%

Aarti Drugs Limited announced its unaudited financial results for the quarter ending 30th June 2025. The company reported a 6% year-over-year (YoY) growth in revenue, which stood at Rs. 590.8 crores. The gross profit margin improved by 130 basis points YoY to 36.8%. EBITDA increased by 12% YoY to Rs. 74 crores, and EBITDA margins improved to 12.6%. The quarter saw improved demand for active pharmaceutical ingredients (APIs), leading to volume recovery and growth. The company incurred a Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration, and finished formulation R&D. Aarti Drugs has started trial productions at its new greenfield manufacturing facility in Sayakha, Gujarat, and expects to begin contributing to its financials from the third quarter onwards. The company is also expanding its Tarapur facility and is strategically positioned to meet the demand shift for pharmaceutical products and APIs imported from countries like China.